Inventiva (NASDAQ:IVA) Shares Gap Up – Still a Buy?

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) gapped up before the market opened on Wednesday . The stock had previously closed at $4.69, but opened at $4.87. Inventiva shares last traded at $4.7950, with a volume of 104,611 shares trading hands.

Wall Street Analysts Forecast Growth

IVA has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Inventiva has a consensus rating of “Buy” and a consensus price target of $16.56.

Inventiva Price Performance

The business has a 50 day simple moving average of $4.31 and a two-hundred day simple moving average of $5.09.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Creative Planning bought a new stake in Inventiva during the 2nd quarter valued at about $32,000. Virtu Financial LLC bought a new position in Inventiva in the 4th quarter worth about $60,000. XTX Topco Ltd bought a new position in Inventiva in the 4th quarter worth about $84,000. Cerity Partners LLC purchased a new position in shares of Inventiva during the fourth quarter worth approximately $93,000. Finally, NewEdge Advisors LLC purchased a new position in shares of Inventiva during the third quarter worth approximately $116,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.